NDP-α-MSH induces intense neurogenesis and cognitive recovery in Alzheimer transgenic mice through activation of melanocortin MC4 receptors
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Melanocortins exert neuroprotection in a variety of experimental neurodegenerative disorders, including Alzheimer's disease (AD). Further, in previous research we showed that these endogenous peptides stimulate neurogenesis in an acute neurodegenerative disorder such as ischemic stroke. In the present research, we investigated the potential neurogenic effect of melanocortins in AD using APPSwe transgenic mice (Tg2576). To this purpose, 24week-old animals were prepared for 5-bromo-2'-deoxyuridine (BrdU) labeling of proliferating cells on days 1-11 of the study. Treatment of Tg2576 mice with nanomolar doses of the melanocortin analog [Nle(4),D-Phe(7)]α-melanocyte-stimulating hormone (NDP-α-MSH), administered once daily from day 1 to 50, improved brain histology and cognitive functions relative to saline-treated Tg2576 animals. No signs of toxicity were observed. Immunohistochemical examination of the hippocampus at the end of the study (day 50) showed that NDP-α-MSH-treated Tg2576 mice had a greater number of BrdU immunoreactive cells colocalized with NeuN (an indicator of mature neurons) and Zif268 (an indicator of functionally integrated neurons) in the dentate gyrus, relative to saline-treated Tg2576 animals; no newly formed astrocytes were found. Animal pretreatment with the selective melanocortin MC4 receptor antagonist HS024 before each NDP-α-MSH administration prevented all the beneficial effects of the peptide. The present data indicate that MC4 receptor stimulation by a melanocortin prevents cognitive decline in experimental AD, this effect being associated not only with neuroprotection but also with an intense neurogenesis. MC4 receptor agonists could be innovative and safe candidates to counteract AD progression in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 2×
“However, disappointing results are arising from these novel studies (Salloway et al., 2014), and, therefore, effective approaches to slow down AD progression are still unavailable in clinical practice.”
Cost of disorders of the brain in Europe 2010
Gustavsson, A., Svensson, M., Jacobi, F., Allgulander, C., Alonso, J., Beghi, E., Dodel, R., Ekman, M., Faravelli, C., Fratiglioni, L., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.08.008 · Cited by 1,723
VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia
Sun, Y., Jin, K., Xie, L., Childs, J., Mao, X. O., Logvinova, A., & Greenberg, D. A. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317977 · Cited by 1,189
Adult hippocampal neurogenesis and its role in Alzheimer’s disease
Mu, Y., & Gage, F. H. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-85 · Cited by 1,021
Increased hippocampal neurogenesis in Alzheimer's disease
Jin, K., Peel, A. L., Mao, X. O., Xie, L., Cottrell, B. A., Henshall, D. C., & Greenberg, D. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2634794100 · Cited by 971 · cited 1×
“…is impaired in AD (Becker et al., 2007; Benarroch, 2013; Ben Menachem-Zidon et al., 2014; Boekhoorn et al., 2006; Iqbal and Grundke-Iqbal, 2011; Jin et al., 2004; Lazarov et al., 2010; Lichtenwalner and Parent, 2006; Lilja et al., 2013; Marlatt and Lucassen, 2010; Mu and Gage, 2011; Perry et…”
Targeting melanocortin receptors as a novel strategy to control inflammation
Catania, A., Gatti, S., Colombo, G., & Lipton, J. M. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.1.1 · Cited by 438
Preclinical Alzheimer disease—the challenges ahead
Sperling, R. A., Karlawish, J., & Johnson, K. A. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.241 · Cited by 291 · cited 2×
“Therefore the aging of human population worldwide and the consequent increase in AD incidence represent a real social and economic alarm (Freiherr et al., 2013; Gustavsson et al., 2011; Ittner and Götz, 2011; Sperling et al., 2013).”
Successful therapies for Alzheimer’s disease: why so many in animal models and none in humans?
Franco, R., & Cedazo-Minguez, A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00146 · Cited by 183
Marlatt, M. W., Potter, M. C., Bayer, T. A., van Praag, H., & Lucassen, P. J. (2013) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2012_237 · Cited by 92 · cited 1×
“Indeed, it has been reported that prolonged exercise increased neurogenesis in triple-transgenic AD mice without reducing neuropathology, that is, Aβ and hyperphosphorylated tau accumulation; surprisingly, these mice did not exhibit learning and memory impairment (Marlatt et al., 2013), thus suggesting, among other, t…”
Neuroprotection in focal cerebral ischemia owing to delayed treatment with melanocortins
Giuliani, D., Ottani, A., Mioni, C., Bazzani, C., Galantucci, M., Minutoli, L., Bitto, A., Zaffe, D., Botticelli, A. R., Squadrito, F., et al. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.05.025 · Cited by 44 · cited 8×
“The mouse ability to learn and recall was evaluated by means of the Morris water-maze test with minor modifications, as previously described in our papers (Bitto et al., 2012; Giuliani et al., 2006, 2007, 2009, 2011, 2013, 2014a, 2014b; Spaccapelo et al., 2011, 2013).”
InfluentialSelf-citation
Cited by
The melanocortin pathway and control of appetite-progress and therapeutic implications
Baldini, G., & Phelan, K. D. (2019) · Journal of Endocrinology · doi:10.1530/joe-18-0596 · Cited by 272
Montero-Melendez, T., Nagano, A., Chelala, C., Filer, A., Buckley, C. D., & Perretti, M. (2020) · Nature Communications · doi:10.1038/s41467-020-14421-x · Cited by 75
Giuliani, D., Ottani, A., Neri, L., Zaffe, D., Grieco, P., Jochem, J., Cavallini, G. M., Catania, A., & Guarini, S. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.11.004 · Cited by 38
Self-citationMelanocortins, Melanocortin Receptors and Multiple Sclerosis
Lisak, R., & Benjamins, J. (2017) · Brain Sciences · doi:10.3390/brainsci7080104 · Cited by 27
Metadata
- Authors
- Giuliani, D., Neri, L., Canalini, F., Calevro, A., Ottani, A., Vandini, E., Sena, P., Zaffe, D., & Guarini, S.
- Venue
- Molecular and Cellular Neuroscience
- Publisher
- Elsevier BV
- Published
- 2015-07
- Volume
- 67
- Pages
- 13-21
- ISSN
- 1044-7431 (ISSN-L)
- OpenAlex
- W1498959868
- Cited by
- 42
- References
- 11
- FWCI
- 3.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.